Management of Bupropion-Naltrexone with Escitalopram

Key Safety Considerations

The American Gastroenterological Association recommends monitoring closely for neuropsychiatric adverse effects including anxiety, depression, suicidal ideation, and mood changes when using bupropion-naltrexone for weight loss alongside escitalopram for menopause symptoms 1, 2
Studies show no significant difference in depression rates between naltrexone-bupropion and placebo (0.1%-1.3% vs 0.2%-1.6%), and anxiety rates were similar (0.6%-5.4% vs 0.2%-4.3%) 1, 2
The combination of bupropion with escitalopram addresses complementary neurotransmitter pathways, which can be beneficial but requires vigilance 3
Regular blood pressure checks are necessary, particularly in the first 8 weeks of treatment, as modest but statistically significant increases in systolic and diastolic blood pressure have been observed with naltrexone-bupropion 1, 2
Bupropion lowers seizure threshold; avoid in patients with seizure disorders or conditions that increase seizure risk (eating disorders, abrupt alcohol/benzodiazepine discontinuation) 1, 2, 3

The maintenance dose should be 2 tablets twice daily (each tablet contains 8 mg naltrexone/90 mg bupropion) 1, 2
Titration schedule: Start with 1 tablet daily in the morning, increase weekly to 1 tablet twice daily, then 2 tablets AM and 1 tablet afternoon, finally reaching 2 tablets twice daily 1, 2
The second dose should not be taken late in the day to minimize insomnia risk 1, 2, 3
For moderate to severe renal impairment: reduce total daily dose by half (1 tablet twice daily); avoid in end-stage renal disease 1, 2, 3
For moderate to severe hepatic impairment: do not exceed 1 tablet daily 1, 2, 3

If the patient has not lost at least 5% of baseline body weight at 12 weeks on maintenance dose, discontinue naltrexone-bupropion as they are likely a poor responder 4, 1, 2

No significant pharmacokinetic interaction exists between bupropion and escitalopram that would require dose adjustment 3
However, be aware that bupropion inhibits CYP2D6, which could theoretically affect other medications metabolized by this pathway 4
Avoid concurrent use with MAOIs or within 14 days of MAOI discontinuation 3
Naltrexone-bupropion must be discontinued before procedures requiring opioid analgesia (e.g., endoscopies with fentanyl) 1, 2

Weekly to biweekly blood pressure checks during titration and first 8 weeks 1, 2
Assess for neuropsychiatric symptoms at each visit, particularly mood changes, anxiety, or suicidal ideation 1, 2
Monitor tolerability of gastrointestinal side effects 1, 2
Weight assessment at 12 weeks to determine continuation (must achieve ≥5% weight loss) 4, 1, 2
Continue periodic blood pressure and heart rate monitoring 1, 2
Ongoing psychiatric symptom surveillance, especially if patient is under 24 years old 3